DK0776339T3 - MHC-komplekser og anvendelser deraf - Google Patents

MHC-komplekser og anvendelser deraf

Info

Publication number
DK0776339T3
DK0776339T3 DK95930790T DK95930790T DK0776339T3 DK 0776339 T3 DK0776339 T3 DK 0776339T3 DK 95930790 T DK95930790 T DK 95930790T DK 95930790 T DK95930790 T DK 95930790T DK 0776339 T3 DK0776339 T3 DK 0776339T3
Authority
DK
Denmark
Prior art keywords
applications
mhc complexes
mhc
complexes
Prior art date
Application number
DK95930790T
Other languages
English (en)
Other versions
DK0776339T4 (da
Inventor
Hing C Wong
Peter R Rhode
Jon A Weidanz
Susan Grammer
Ann C Edwards
Pierre-Andre Chavaillaz
Jin-An Jiao
Original Assignee
Sunol Molecular Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26961973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0776339(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sunol Molecular Corp filed Critical Sunol Molecular Corp
Publication of DK0776339T3 publication Critical patent/DK0776339T3/da
Application granted granted Critical
Publication of DK0776339T4 publication Critical patent/DK0776339T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95930790.1T 1994-07-29 1995-07-31 MHC-komplekser og anvendelser deraf DK0776339T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28330294A 1994-07-29 1994-07-29
US38245495A 1995-02-01 1995-02-01
PCT/US1995/009816 WO1996004314A1 (en) 1994-07-29 1995-07-31 Mhc complexes and uses thereof

Publications (2)

Publication Number Publication Date
DK0776339T3 true DK0776339T3 (da) 2001-02-05
DK0776339T4 DK0776339T4 (da) 2010-05-25

Family

ID=26961973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95930790.1T DK0776339T4 (da) 1994-07-29 1995-07-31 MHC-komplekser og anvendelser deraf

Country Status (8)

Country Link
EP (2) EP0997477B1 (da)
JP (1) JPH10503379A (da)
AU (1) AU696177B2 (da)
CA (1) CA2196085C (da)
DE (2) DE69519101T3 (da)
DK (1) DK0776339T4 (da)
ES (1) ES2152424T5 (da)
WO (1) WO1996004314A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
US6140113A (en) * 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
AU770938B2 (en) * 1996-03-28 2004-03-11 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
KR100544449B1 (ko) * 1996-03-28 2006-10-31 더 존스 홉킨스 유니버시티 단백질의 가용성2가 및 다가 헤테로 이량체 유사체
NZ331688A (en) * 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
JP2000516470A (ja) * 1996-08-16 2000-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 可溶性一価および多価ｍｈｃクラスｉｉ融合タンパク質およびそれらの使用
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
CA2302779C (en) * 1997-09-16 2010-02-02 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
AU2002301994B2 (en) * 1998-06-05 2008-05-15 Alexis Biotech Limited Method for producing cytotoxic T-cells
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
GB2339782A (en) 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1287363A2 (en) * 2000-05-25 2003-03-05 Sunol Molecular Corporation Modulation of t-cell receptor interactions
US20020061587A1 (en) 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CA2487779C (en) 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
DE60334474D1 (de) * 2002-07-12 2010-11-18 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
US8377447B2 (en) 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
DE102004019803A1 (de) * 2004-04-23 2005-11-10 Imusyn Gmbh & Co.Kg Verfahren zur Herstellung löslicher MHC-Proteine
KR101442209B1 (ko) 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 융합 단백질, 이의 용도 및 이의 제조방법
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP3013361B1 (en) * 2013-06-24 2021-10-06 NexImmune, Inc. Compositions and methods for immunotherapy
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
EP3772927B1 (en) * 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
JP2022522405A (ja) * 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
EP3935079A4 (en) * 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
EP4232468A4 (en) * 2020-10-20 2025-03-19 Replay Holdings, Inc. Methods and compositions for cellular therapy
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924850T2 (de) * 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
AU3220693A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
AU6715094A (en) * 1993-04-29 1994-11-21 Andrew Atkin Recombinant vaccine
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
CA2224205A1 (en) * 1995-06-07 1996-12-19 Zymogenetics, Inc. Fused soluble mhc heterodimer-peptide complexes and their uses

Also Published As

Publication number Publication date
EP0776339B1 (en) 2000-10-11
DE69519101T3 (de) 2010-08-05
EP0776339A1 (en) 1997-06-04
DE69534880D1 (de) 2006-05-11
JPH10503379A (ja) 1998-03-31
EP0997477A3 (en) 2002-07-10
DK0776339T4 (da) 2010-05-25
CA2196085C (en) 2002-12-10
DE69534880T2 (de) 2007-02-22
DE69519101D1 (de) 2000-11-16
EP0997477B1 (en) 2006-03-15
WO1996004314A1 (en) 1996-02-15
DE69519101T2 (de) 2001-05-17
AU3403995A (en) 1996-03-04
EP0997477A2 (en) 2000-05-03
ES2152424T3 (es) 2001-02-01
EP0776339A4 (en) 1997-10-29
EP0776339B2 (en) 2010-01-20
AU696177B2 (en) 1998-09-03
ES2152424T5 (es) 2010-07-05
CA2196085A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
DK0776339T4 (da) MHC-komplekser og anvendelser deraf
IS4481A (is) Díhýdrópyramídín og notkun þeirra
NO20001307L (no) Cyklopentafenantreneyl-metallkomplekser og polymerisasjonsprosess
NO961425D0 (no) 1N-alkyl-N-arylpyrimidinaminer og derivater derav
DK0820459T3 (da) Organoboran-polyoxyalkylenpolyamin-komplekser og adhæsivsammensætninger fremstillet dermed
NO951436D0 (no) CTLA4-Molekyler og IL-4-bindingsmolekyler og anvendelser derav
NO20011821D0 (no) Arbeidsromorganisering og möbelsystem
NO912589D0 (no) Anti-plakk og anti-tannsten tannpasta.
NO922118D0 (no) Kabelskjoeter og kabelavslutninger
NO943763D0 (no) 4-arylamino-benzopyraner og beslektede forbindelser
DK0804078T3 (da) Sammensætning og anvendelse deraf
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
NO995811L (no) Selvgjenopprettende og selvbekreftende kryptosystemer
DK0719790T3 (da) Metalchelatdannende peptider og anvendelser deraf
DE69518687D1 (de) Versorgung-unterscheidendes und Versorgung-adaptierendes elektronisches System
NO913444D0 (no) Polyetylenblandinger og anvendelse derav.
NO983556D0 (no) Formulering og anvendelse
DE69417452D1 (de) Buchklammer und lesezeichen
BR9507133A (pt) N-aril e n-alquilsulfonilaminais
NO952766L (no) Opplösningsmiddelsammensetninger og metoder
DE59405056D1 (de) Drilleiter
DK8690D0 (da) Forbindelser og anvendelse
DK8590D0 (da) Forbindelser og anvendelse
DK36390D0 (da) Forbindelser og anvendelse
ITMI941026A1 (it) Azaciclo e azabiciclo ammidi